WO2009100871A3 - Drug delivery system with stabilising effect - Google Patents

Drug delivery system with stabilising effect Download PDF

Info

Publication number
WO2009100871A3
WO2009100871A3 PCT/EP2009/000904 EP2009000904W WO2009100871A3 WO 2009100871 A3 WO2009100871 A3 WO 2009100871A3 EP 2009000904 W EP2009000904 W EP 2009000904W WO 2009100871 A3 WO2009100871 A3 WO 2009100871A3
Authority
WO
WIPO (PCT)
Prior art keywords
delivery system
drug delivery
film matrix
stabilising effect
graft copolymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2009/000904
Other languages
French (fr)
Other versions
WO2009100871A2 (en
Inventor
Adrian Funke
Ildiko Terebesi
Sascha General
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Schering Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40957307&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2009100871(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CA2714598A priority Critical patent/CA2714598A1/en
Priority to EA201001244A priority patent/EA018330B1/en
Priority to EP09710685A priority patent/EP2252261A2/en
Priority to UAA201010636A priority patent/UA102680C2/en
Priority to CN2009801052087A priority patent/CN102006857B/en
Application filed by Bayer Schering Pharma AG filed Critical Bayer Schering Pharma AG
Priority to NZ587309A priority patent/NZ587309A/en
Priority to MX2010008945A priority patent/MX2010008945A/en
Priority to BRPI0908231-0A priority patent/BRPI0908231A2/en
Priority to JP2010546253A priority patent/JP2011511816A/en
Priority to AU2009214307A priority patent/AU2009214307A1/en
Priority to US12/867,165 priority patent/US20110052699A1/en
Priority to TW098126657A priority patent/TW201008569A/en
Priority to EA201100304A priority patent/EA201100304A1/en
Priority to CN2009801310695A priority patent/CN102119021A/en
Priority to EP09781632A priority patent/EP2331067A1/en
Priority to JP2011521597A priority patent/JP2011530499A/en
Priority to PCT/EP2009/060298 priority patent/WO2010015713A1/en
Priority to PE2011000137A priority patent/PE20110573A1/en
Priority to KR1020117002831A priority patent/KR20110044752A/en
Priority to BRPI0917030A priority patent/BRPI0917030A2/en
Priority to AU2009279053A priority patent/AU2009279053A1/en
Priority to US13/057,299 priority patent/US20110293720A1/en
Priority to MX2011001519A priority patent/MX2011001519A/en
Priority to CA2732211A priority patent/CA2732211A1/en
Priority to ARP090103070A priority patent/AR072933A1/en
Priority to UY0001032041A priority patent/UY32041A/en
Publication of WO2009100871A2 publication Critical patent/WO2009100871A2/en
Publication of WO2009100871A3 publication Critical patent/WO2009100871A3/en
Priority to IL206927A priority patent/IL206927A0/en
Priority to MA33052A priority patent/MA32055B1/en
Priority to TNP2010000375A priority patent/TN2010000375A1/en
Anticipated expiration legal-status Critical
Priority to ZA2010/06518A priority patent/ZA201006518B/en
Priority to IL210590A priority patent/IL210590A0/en
Priority to MA33583A priority patent/MA32538B1/en
Priority to EC2011010815A priority patent/ECSP11010815A/en
Priority to SV2011003835A priority patent/SV2011003835A/en
Priority to ZA2011/01737A priority patent/ZA201101737B/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)

Abstract

A drug delivery system also intended as unit dosage form comprising a thin water-soluble film matrix, wherein said film matrix comprises a) a polyvinyl alcohol-polyethylene glycol graft copolymer (PVA-PEG graft copolymer) as a water-soluble matrix polymer; b) an active ingredient being a steroid in which the positions 6 and 7 of the steroidal skeleton are both a -CH2- residue; and said film matrix has a thickness of less than 300 μm.
PCT/EP2009/000904 2008-02-13 2009-02-10 Drug delivery system with stabilising effect Ceased WO2009100871A2 (en)

Priority Applications (35)

Application Number Priority Date Filing Date Title
US12/867,165 US20110052699A1 (en) 2008-02-13 2009-02-10 Drug delivery system with stabilising effect
EA201001244A EA018330B1 (en) 2008-02-13 2009-02-10 Drug delivery system with stabilising effect
EP09710685A EP2252261A2 (en) 2008-02-13 2009-02-10 Drug delivery system with stabilising effect
UAA201010636A UA102680C2 (en) 2008-02-13 2009-02-10 Unit dosage form comprising a polyvinyl alcohol-polyethylene glycol graft copolymer and steroidal estrogen
CN2009801052087A CN102006857B (en) 2008-02-13 2009-02-10 Drug delivery system with stabilising effect
CA2714598A CA2714598A1 (en) 2008-02-13 2009-02-10 Drug delivery system with stabilising effect
NZ587309A NZ587309A (en) 2008-02-13 2009-02-10 Wafer film systems for for the delivery of estrogen or progestin
MX2010008945A MX2010008945A (en) 2008-02-13 2009-02-10 Drug delivery system with stabilising effect.
BRPI0908231-0A BRPI0908231A2 (en) 2008-02-13 2009-02-10 Stabilizing drug release system
JP2010546253A JP2011511816A (en) 2008-02-13 2009-02-10 Drug delivery system with stabilizing effect
AU2009214307A AU2009214307A1 (en) 2008-02-13 2009-02-10 Drug delivery system with stabilising effect
TW098126657A TW201008569A (en) 2008-08-08 2009-08-06 Progestin-containing drug delivery system
BRPI0917030A BRPI0917030A2 (en) 2008-08-08 2009-08-07 progestin-containing drug delivery system
KR1020117002831A KR20110044752A (en) 2008-08-08 2009-08-07 Progestin-containing drug delivery system
CA2732211A CA2732211A1 (en) 2008-08-08 2009-08-07 Progestin-containing drug delivery system
EP09781632A EP2331067A1 (en) 2008-08-08 2009-08-07 Progestin-containing drug delivery system
JP2011521597A JP2011530499A (en) 2008-08-08 2009-08-07 Drug delivery system containing progestin
PCT/EP2009/060298 WO2010015713A1 (en) 2008-08-08 2009-08-07 Progestin-containing drug delivery system
PE2011000137A PE20110573A1 (en) 2008-08-08 2009-08-07 PROGESTIN-CONTAINING DRUG ADMINISTRATION SYSTEM
EA201100304A EA201100304A1 (en) 2008-08-08 2009-08-07 DELIVERY SYSTEM OF MEDICINES CONTAINING PROGESTINS
CN2009801310695A CN102119021A (en) 2008-08-08 2009-08-07 Progestin-containing drug delivery system
AU2009279053A AU2009279053A1 (en) 2008-08-08 2009-08-07 Progestin-containing drug delivery system
US13/057,299 US20110293720A1 (en) 2008-08-08 2009-08-07 Progestin-containing drug delivery system
MX2011001519A MX2011001519A (en) 2008-08-08 2009-08-07 Progestin-containing drug delivery system.
UY0001032041A UY32041A (en) 2008-08-08 2009-08-10 DRUG ADMINISTRATION SYSTEM WITH PROGESTINE CONTENT
ARP090103070A AR072933A1 (en) 2008-08-08 2009-08-10 DRUG ADMINISTRATION SYSTEM WITH PROGESTINE CONTENT
IL206927A IL206927A0 (en) 2008-02-13 2010-07-11 Drug delivery system with stabilising effect
MA33052A MA32055B1 (en) 2008-02-13 2010-08-02 System to give drugs that help balance
TNP2010000375A TN2010000375A1 (en) 2009-02-10 2010-08-11 Drug delivery system with stabilising effect
ZA2010/06518A ZA201006518B (en) 2008-02-13 2010-09-10 Drug delivery system with stabilising effect
IL210590A IL210590A0 (en) 2008-08-08 2011-01-12 Progestin-cotaining drug delivery system
MA33583A MA32538B1 (en) 2008-08-08 2011-02-04 Progestogen-containing drug delivery system
EC2011010815A ECSP11010815A (en) 2008-08-08 2011-02-08 DRUG ADMINISTRATION SYSTEM CONTAINING PROGESTINE
SV2011003835A SV2011003835A (en) 2008-08-08 2011-02-08 DRUG ADMINISTRATION SYSTEM CONTAINING PROGESTINE
ZA2011/01737A ZA201101737B (en) 2008-08-08 2011-03-07 Progestin-containing drug delivery system

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP08002633.9 2008-02-13
EP08002633 2008-02-13
EP08162105 2008-08-08
EP08162105.4 2008-08-08
EP08105842.2 2008-11-21
EP08105842 2008-11-21

Publications (2)

Publication Number Publication Date
WO2009100871A2 WO2009100871A2 (en) 2009-08-20
WO2009100871A3 true WO2009100871A3 (en) 2009-12-23

Family

ID=40957307

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/000904 Ceased WO2009100871A2 (en) 2008-02-13 2009-02-10 Drug delivery system with stabilising effect

Country Status (26)

Country Link
US (1) US20110052699A1 (en)
EP (1) EP2252261A2 (en)
JP (1) JP2011511816A (en)
KR (1) KR20100117603A (en)
CN (1) CN102006857B (en)
AR (1) AR070379A1 (en)
AU (1) AU2009214307A1 (en)
BR (1) BRPI0908231A2 (en)
CA (1) CA2714598A1 (en)
CL (1) CL2009000328A1 (en)
CO (1) CO6321222A2 (en)
CR (1) CR11630A (en)
DO (1) DOP2010000253A (en)
EA (1) EA018330B1 (en)
EC (1) ECSP10010399A (en)
HN (1) HN2010001610A (en)
IL (1) IL206927A0 (en)
MA (1) MA32055B1 (en)
MX (1) MX2010008945A (en)
NZ (1) NZ587309A (en)
PA (1) PA8815901A1 (en)
PE (1) PE20091574A1 (en)
TW (1) TW200940069A (en)
UY (1) UY31659A1 (en)
WO (1) WO2009100871A2 (en)
ZA (1) ZA201006518B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012509286A (en) * 2008-11-21 2012-04-19 バイエル ファーマ アクチエンゲゼルシャフト Drug delivery system
CN102018657B (en) * 2009-09-11 2014-01-22 上海市计划生育科学研究所 Solid dispersoid containing progestational hormone, preparation method thereof and composite comprising same
HUP0900698A2 (en) * 2009-11-06 2011-06-28 Richter Gedeon Nyrt Pharmaceutical compositions of enhanced stability containing drospirenone and ethynyl estradiol and process for their preparation
AR081670A1 (en) 2010-06-29 2012-10-10 Leon Farma Sa Lab PHARMACEUTICAL COMPOSITION INCLUDING DROSPIRENONE AND ANTI-ECONCEPTIVE KIT
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
WO2014018075A1 (en) 2012-07-23 2014-01-30 Crayola, Llc Dissolvable films and methods of using the same
EP3179985A1 (en) * 2014-08-14 2017-06-21 Brown University Compositions for stabilizing and delivering proteins
TWI525110B (en) * 2014-12-24 2016-03-11 財團法人工業技術研究院 Polymer, and pharmaceutical composition employing the same
JPWO2016163403A1 (en) * 2015-04-07 2018-02-01 ニプロ株式会社 Oral film formulation
WO2017094856A1 (en) * 2015-12-02 2017-06-08 株式会社日本触媒 Water-soluble film and manufacturing method therefor
WO2020006073A1 (en) 2018-06-28 2020-01-02 Arx, Llc Dispensing method for producing dissolvable unit dose film constructs
JP7353364B2 (en) * 2018-07-11 2023-09-29 キュア ファーマシューティカル， インコーポレイテッド Rapidly disintegrating film matrix in the oral cavity
CN116887866A (en) 2020-12-03 2023-10-13 巴特尔纪念研究院 Polymer nanoparticle and DNA nanostructure compositions and methods for non-viral delivery
JP2024516108A (en) 2021-04-07 2024-04-12 バテル・メモリアル・インスティテュート Rapid Design, Build, Test, and Learn Techniques for Identifying and Using Nonviral Carriers
CN115624566B (en) * 2022-12-22 2023-03-10 广东省人民医院 A kind of peritoneal dialysis fluid and its preparation method and application
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003104253A2 (en) * 2002-06-11 2003-12-18 Schering Aktiengesellschaft 9-alpha-substituted estratrienes as selectively active estrogen
WO2005110358A2 (en) * 2004-05-14 2005-11-24 Hf Arzneimittelforschung Gmbh Film-shaped estriol-containing medicament for oral administration
DE102005058569A1 (en) * 2005-12-08 2007-06-14 Lts Lohmann Therapie-Systeme Ag Foam wafer with polyvinyl alcohol-polyethylene glycol graft copolymer
DE102006027796A1 (en) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Estrogen-progestogen combinations
DE102006027792A1 (en) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Antidepressants Combination wafer

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136162A (en) * 1974-07-05 1979-01-23 Schering Aktiengesellschaft Medicament carriers in the form of film having active substance incorporated therein
JPS56140915A (en) * 1980-04-07 1981-11-04 Yamanouchi Pharmaceut Co Ltd Pharmaceutical preparation for solid drug
DE3347125A1 (en) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen MULTI-STAGE COMBINATION PREPARATION AND ITS USE FOR ORAL CONTRACTION
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
ES2105262T3 (en) * 1992-05-18 1997-10-16 Minnesota Mining & Mfg PHARMACY SUPPLY DEVICE THROUGH THE MUCOSAS.
DE4426709A1 (en) * 1994-07-20 1996-01-25 Schering Ag Solid dosage forms containing steroidal sex hormones
DE19646392A1 (en) * 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Preparation for use in the oral cavity with a layer containing pressure-sensitive adhesive, pharmaceuticals or cosmetics for dosed delivery
US6552024B1 (en) * 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
CH693905A5 (en) * 1999-04-15 2004-04-15 Eprova Ag Stable crystalline salts of 5-methyl tetrahydrofolic acid.
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US20050074487A1 (en) * 1999-12-16 2005-04-07 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US20030092658A1 (en) * 2001-02-02 2003-05-15 Meyers Rachel E. Novel human enzyme family members and uses thereof
SK14632002A3 (en) * 2000-04-12 2003-03-04 Schering Aktiengesellschaft 8Beta-hydrocarbyl-substituted estratrienes for use as selective estrogens
EP1216712A1 (en) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Cyclodextrin-drospirenone inclusion complexes
MXPA03000985A (en) * 2001-07-27 2004-04-02 Yamanouchi Pharma Co Ltd Compositions containing sustained-release fine grains for tablets quickly disintegrable in the oral cavity and process for producing the same.
US20040208931A1 (en) * 2002-12-30 2004-10-21 Friend David R Fast dissolving films for oral administration of drugs
EP1648362A4 (en) * 2003-07-01 2012-01-11 Todd Maibach FILM CONTAINING THERAPEUTIC AGENTS
PL2446881T3 (en) * 2003-07-24 2014-08-29 Glaxosmithkline Llc Orally Dissolving Films
CN1913876B (en) * 2003-12-09 2013-06-26 大日本住友制药株式会社 Drug-containing grains and solid preparation containing the grains
US20050220825A1 (en) * 2004-03-10 2005-10-06 Adrian Funke Molecular dispersions of drospirenone
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
DE102005015128B4 (en) * 2005-03-31 2008-12-11 Bayer Schering Pharma Aktiengesellschaft Wafers containing steroid hormones
DE102005062270A1 (en) * 2005-12-24 2007-06-28 Bayer Technology Services Gmbh Coated solid material, useful e.g. as powder-inhalant or oral dosage form, comprises a powdery solid material and a coating from a hydrophobic enveloping material
DE102006003512A1 (en) * 2006-01-24 2007-08-02 Bayer Schering Pharma Ag Film-forming transmucosal medicament, useful for administering active agents such as androgens, gestagens and estrogens, comprises a film former, which disintegrates in an aqueous medium, and cyclodextrin or its derivatives
GB0607105D0 (en) * 2006-04-10 2006-05-17 Leuven K U Res & Dev Enhancing solubility and dissolution rate of poorly soluble drugs

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003104253A2 (en) * 2002-06-11 2003-12-18 Schering Aktiengesellschaft 9-alpha-substituted estratrienes as selectively active estrogen
WO2005110358A2 (en) * 2004-05-14 2005-11-24 Hf Arzneimittelforschung Gmbh Film-shaped estriol-containing medicament for oral administration
DE102005058569A1 (en) * 2005-12-08 2007-06-14 Lts Lohmann Therapie-Systeme Ag Foam wafer with polyvinyl alcohol-polyethylene glycol graft copolymer
DE102006027796A1 (en) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Estrogen-progestogen combinations
DE102006027792A1 (en) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Antidepressants Combination wafer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Kollicoat IR", TECHNICAL INFORMATION BASF, XX, XX, 1 July 2006 (2006-07-01), pages 1 - 12, XP002429201 *

Also Published As

Publication number Publication date
DOP2010000253A (en) 2010-08-31
MX2010008945A (en) 2010-09-07
WO2009100871A2 (en) 2009-08-20
CR11630A (en) 2010-10-05
CO6321222A2 (en) 2011-09-20
PE20091574A1 (en) 2009-11-12
EA018330B1 (en) 2013-07-30
CA2714598A1 (en) 2009-08-20
UY31659A1 (en) 2009-09-30
CN102006857A (en) 2011-04-06
ECSP10010399A (en) 2010-09-30
KR20100117603A (en) 2010-11-03
NZ587309A (en) 2012-09-28
IL206927A0 (en) 2010-12-30
US20110052699A1 (en) 2011-03-03
BRPI0908231A2 (en) 2015-07-21
JP2011511816A (en) 2011-04-14
CN102006857B (en) 2013-06-26
CL2009000328A1 (en) 2010-07-19
EP2252261A2 (en) 2010-11-24
PA8815901A1 (en) 2009-09-17
AR070379A1 (en) 2010-03-31
TW200940069A (en) 2009-10-01
EA201001244A1 (en) 2011-04-29
MA32055B1 (en) 2011-02-01
ZA201006518B (en) 2013-02-27
AU2009214307A1 (en) 2009-08-20
HN2010001610A (en) 2013-10-20

Similar Documents

Publication Publication Date Title
MX2010008945A (en) Drug delivery system with stabilising effect.
WO2010006143A3 (en) Transdermal estrogen device and delivery
WO2008100375A3 (en) Polymer-based films and drug delivery systems made therefrom
WO2009061607A3 (en) Water-immiscible materials as vehicles for drug delivery
MX2010004789A (en) TRANSDERMAL RELEASE SYSTEM FOR HORMONES AND STEROIDS.
WO2008120207A3 (en) Compositions for nasal delivery
WO2007115381A3 (en) Solid dispersion of poorly soluble drugs in graft copolymers
AU2007304471A1 (en) Controlled release delivery system for nasal application of neurotransmitters
NZ612326A (en) Biodegradable drug delivery compositions
WO2008008364A3 (en) Enhanced stability phenylephrine liquid compositions
WO2008005176A3 (en) Electroactive polymer radiopaque marker
WO2007106386A3 (en) Nozzle pore configuration for intrapulmonary delivery of aerosolized formulations
WO2006101882A3 (en) Medicament delivery formulations, devices and methods
WO2007135193A3 (en) Sustained-release alcohol-resistant multimicroparticulate oral pharmaceutical form comprising anti-misuse means
WO2008149192A3 (en) Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
WO2007035940A3 (en) Transdermal norelgestromin delivery system
WO2009014827A3 (en) Medical devices comprising polymeric drug delivery systems with drug solubility gradients
WO2008152398A3 (en) Formulations for inhalation
FI3294300T3 (en) LONG-ACTING DRUG DELIVERY DEVICE IN THE FORM OF AN IMPLANT OR IUD CONTAINING LEVONORGESTREL AND ETHINYL ESTRADIOL
WO2008107301A3 (en) Rapid-disintegration monolayer film for the oral administration of active substances
WO2007122510A3 (en) Asymmetric membranes for drug delivery devices
WO2009076272A3 (en) Drug coated stent with endosome-disrupting conjugate
WO2014016671A3 (en) Formulations and methods of manufacturing formulations for use in colonic evacuation
UA102680C2 (en) Unit dosage form comprising a polyvinyl alcohol-polyethylene glycol graft copolymer and steroidal estrogen
WO2011119288A3 (en) Multilayer melt-extruded film

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980105208.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09710685

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009710685

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 206927

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2009214307

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2714598

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2009214307

Country of ref document: AU

Date of ref document: 20090210

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: DZP2010000502

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 587309

Country of ref document: NZ

Ref document number: PI 2010003341

Country of ref document: MY

Ref document number: 5666/DELNP/2010

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 1001125

Country of ref document: KE

ENP Entry into the national phase

Ref document number: 20107017866

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010546253

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 10100007

Country of ref document: CO

Ref document number: 201011630

Country of ref document: CR

Ref document number: D2010165

Country of ref document: CU

Ref document number: 12010501845

Country of ref document: PH

Ref document number: MX/A/2010/008945

Country of ref document: MX

Ref document number: CR2010-011630

Country of ref document: CR

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 201001244

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: A201010636

Country of ref document: UA

ENP Entry into the national phase

Ref document number: PI0908231

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100813